# ZMAT1

## Overview
ZMAT1 (zinc finger matrin-type 1) is a gene that encodes a nuclear protein characterized by zinc finger motifs, which are critical for its role in binding nucleic acids and regulating gene expression. The protein, also named zinc finger matrin-type 1, is involved in transcriptional and post-transcriptional processes, playing a significant role in cellular homeostasis and the regulation of the cell cycle and apoptosis. It is particularly noted for its involvement in the p53 signaling pathway, where it acts as a transcriptional activator for SIRT3, an upstream regulator of p53, thereby influencing cell cycle progression and apoptosis. ZMAT1 has been identified as a tumor suppressor in pancreatic ductal adenocarcinoma (PDAC), where its expression is often down-regulated, correlating with poor clinical outcomes. Beyond cancer, alterations in ZMAT1 have been implicated in congenital abnormalities, although specific clinical associations remain under investigation (Ma2022ZMAT1; Cao2016A).

## Function
ZMAT1 (zinc finger matrin-type 1) is a gene that encodes a protein involved in RNA processing and gene expression regulation. The protein contains zinc finger motifs, which facilitate binding to nucleic acids, influencing transcriptional and post-transcriptional processes. ZMAT1 is active in the nucleus, contributing to cellular homeostasis and gene expression modulation. In healthy human cells, ZMAT1 plays a crucial role in regulating the cell cycle and apoptosis. It is involved in pathways such as the p53 signaling pathway and cell cycle regulation, where it influences the expression of genes related to cell cycle progression and apoptosis (Ma2022ZMAT1).

ZMAT1 indirectly influences p53 expression by binding to the promoter region of SIRT3, an upstream regulator of p53, acting as a transcriptional activator for SIRT3. This interaction suggests that ZMAT1 modulates the SIRT3-p53 signaling pathway, which is essential for maintaining normal cellular functions and preventing uncontrolled cell proliferation (Ma2022ZMAT1). The protein's activity in the nucleus and its involvement in these critical pathways underscore its importance in maintaining cellular integrity and preventing tumorigenesis.

## Clinical Significance
ZMAT1 has been identified as a tumor suppressor gene in pancreatic ductal adenocarcinoma (PDAC), a highly aggressive cancer with poor prognosis. Its expression is significantly down-regulated in PDAC, and this reduced expression is associated with unfavorable clinical characteristics, such as poor tumor differentiation, advanced TNM stage, high CA19-9 index, and positive lymph node metastasis. Low ZMAT1 expression is also an independent risk factor for overall survival and disease-free survival in PDAC patients (Ma2022ZMAT1). Overexpression of ZMAT1 inhibits pancreatic cancer cell proliferation by inducing p21, which impairs S/G2 cell cycle progression, and decreases apoptosis. This effect is mediated through the upregulation of p53 expression, although ZMAT1 does not bind directly to p53. Instead, it acts as a transcriptional activator for SIRT3, an upstream regulator of p53, suggesting that the ZMAT1-SIRT3-p53 signaling pathway plays a significant role in tumor growth (Ma2022ZMAT1).

In addition to its role in cancer, a deletion involving ZMAT1 has been reported in a male patient with multiple congenital abnormalities and respiratory failure, suggesting that the loss of ZMAT1 may contribute to these phenotypes (Cao2016A). However, specific clinical associations of ZMAT1 mutations alone are not well-documented.

## Interactions
ZMAT1, a zinc finger matrin-type protein, is involved in transcriptional regulation and interacts with the SIRT3-p53 signaling pathway in pancreatic ductal adenocarcinoma (PDAC). Although ZMAT1 does not directly bind to the p53 gene, it influences p53 expression through its interaction with the SIRT3 promoter. ZMAT1 acts as a transcriptional activator for SIRT3, which is an upstream regulator of p53. This interaction is crucial for the tumor suppressor role of ZMAT1, as it leads to increased expression of p53 and its downstream targets, such as p21, thereby inhibiting cancer cell proliferation and inducing cell cycle arrest at the S/G2 phase (Ma2022ZMAT1).

Chromatin immunoprecipitation (ChIP) assays have confirmed ZMAT1 binding to specific sites in the SIRT3 promoter region. Mutations in these binding sites prevent ZMAT1 from inducing activity in the SIRT3 promoter, highlighting the importance of this interaction in regulating p53 expression (Ma2022ZMAT1). The study also demonstrated that ZMAT1 overexpression leads to increased SIRT3 and p53 levels in tumor tissues, further supporting its role in modulating the SIRT3-p53 pathway (Ma2022ZMAT1).


## References


[1. (Ma2022ZMAT1) Zuyi Ma, Zhenchong Li, Shujie Wang, Zixuan Zhou, Chunsheng Liu, Hongkai Zhuang, Qi Zhou, Shanzhou Huang, Chuanzhao Zhang, and Baohua Hou. Zmat1 acts as a tumor suppressor in pancreatic ductal adenocarcinoma by inducing sirt3/p53 signaling pathway. Journal of Experimental &amp; Clinical Cancer Research, April 2022. URL: http://dx.doi.org/10.1186/s13046-022-02310-8, doi:10.1186/s13046-022-02310-8. This article has 12 citations.](https://doi.org/10.1186/s13046-022-02310-8)

[2. (Cao2016A) Yang Cao and Umut Aypar. A novel xq22.1 deletion in a male with multiple congenital abnormalities and respiratory failure. European Journal of Medical Genetics, 59(5):274â€“277, May 2016. URL: http://dx.doi.org/10.1016/j.ejmg.2016.03.004, doi:10.1016/j.ejmg.2016.03.004. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ejmg.2016.03.004)